768 related articles for article (PubMed ID: 17226956)
1. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
[TBL] [Abstract][Full Text] [Related]
2. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin.
Hong M; Zhu S; Jiang Y; Tang G; Pei Y
J Control Release; 2009 Jan; 133(2):96-102. PubMed ID: 18840485
[TBL] [Abstract][Full Text] [Related]
3. Novel shielded transferrin-polyethylene glycol-polyethylenimine/DNA complexes for systemic tumor-targeted gene transfer.
Kursa M; Walker GF; Roessler V; Ogris M; Roedl W; Kircheis R; Wagner E
Bioconjug Chem; 2003; 14(1):222-31. PubMed ID: 12526712
[TBL] [Abstract][Full Text] [Related]
4. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT).
Maruyama K; Ishida O; Kasaoka S; Takizawa T; Utoguchi N; Shinohara A; Chiba M; Kobayashi H; Eriguchi M; Yanagie H
J Control Release; 2004 Aug; 98(2):195-207. PubMed ID: 15262412
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
6. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles.
Hong M; Zhu S; Jiang Y; Tang G; Sun C; Fang C; Shi B; Pei Y
J Control Release; 2010 Jan; 141(1):22-9. PubMed ID: 19735683
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-alpha: a novel polymer-conjugation technique with a reversible amino-protective reagent.
Tsunoda S; Ishikawa T; Yamamoto Y; Kamada H; Koizumi K; Matsui J; Tsutsumi Y; Hirano T; Mayumi T
J Pharmacol Exp Ther; 1999 Jul; 290(1):368-72. PubMed ID: 10381801
[TBL] [Abstract][Full Text] [Related]
8. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
Tsutsumi Y; Kihira T; Tsunoda S; Kamada H; Nakagawa S; Kaneda Y; Kanamori T; Mayumi T
J Pharmacol Exp Ther; 1996 Sep; 278(3):1006-11. PubMed ID: 8819479
[TBL] [Abstract][Full Text] [Related]
9. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
10. PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting.
Kim TH; Jo YG; Jiang HH; Lim SM; Youn YS; Lee S; Chen X; Byun Y; Lee KC
J Control Release; 2012 Sep; 162(2):422-8. PubMed ID: 22824780
[TBL] [Abstract][Full Text] [Related]
11. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency.
Yoshioka Y; Tsutsumi Y; Ikemizu S; Yamamoto Y; Shibata H; Nishibata T; Mukai Y; Okamoto T; Taniai M; Kawamura M; Abe Y; Nakagawa S; Nagata S; Yamagata Y; Mayumi T
Biochem Biophys Res Commun; 2004 Mar; 315(4):808-14. PubMed ID: 14985084
[TBL] [Abstract][Full Text] [Related]
12. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window.
Shibata H; Yoshioka Y; Ikemizu S; Kobayashi K; Yamamoto Y; Mukai Y; Okamoto T; Taniai M; Kawamura M; Abe Y; Nakagawa S; Hayakawa T; Nagata S; Yamagata Y; Mayumi T; Kamada H; Tsutsumi Y
Clin Cancer Res; 2004 Dec; 10(24):8293-300. PubMed ID: 15623605
[TBL] [Abstract][Full Text] [Related]
13. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
[TBL] [Abstract][Full Text] [Related]
14. Active tumor-targeted delivery of PEG-protein via transferrin-transferrin-receptor system.
Jiang Y; Tang G; Hong M; Zhu S; Fang C; Shi B; Pei Y
J Drug Target; 2007 Dec; 15(10):672-83. PubMed ID: 18041635
[TBL] [Abstract][Full Text] [Related]
15. Transferrin-loaded nido-carborane liposomes: tumor-targeting boron delivery system for neutron capture therapy.
Miyajima Y; Nakamura H; Kuwata Y; Lee JD; Masunaga S; Ono K; Maruyama K
Bioconjug Chem; 2006; 17(5):1314-20. PubMed ID: 16984142
[TBL] [Abstract][Full Text] [Related]
16. In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer.
Anabousi S; Bakowsky U; Schneider M; Huwer H; Lehr CM; Ehrhardt C
Eur J Pharm Sci; 2006 Dec; 29(5):367-74. PubMed ID: 16952451
[TBL] [Abstract][Full Text] [Related]
17. Synergistic targeted delivery of payload into tumor cells by dual-ligand liposomes co-modified with cholesterol anchored transferrin and TAT.
Tang J; Zhang L; Liu Y; Zhang Q; Qin Y; Yin Y; Yuan W; Yang Y; Xie Y; Zhang Z; He Q
Int J Pharm; 2013 Sep; 454(1):31-40. PubMed ID: 23850793
[TBL] [Abstract][Full Text] [Related]
18. Constructing transferrin receptor targeted drug delivery system by using doxorubicin hydrochloride and vanadocene dichloride.
Zhang Y; Xiang J; Liu Y; Zhang X; Tang Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5982-6. PubMed ID: 21862329
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of tumor necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid tumors in mice.
Kamada H; Tsutsumi Y; Yamamoto Y; Kihira T; Kaneda Y; Mu Y; Kodaira H; Tsunoda SI; Nakagawa S; Mayumi T
Cancer Res; 2000 Nov; 60(22):6416-20. PubMed ID: 11103807
[TBL] [Abstract][Full Text] [Related]
20. The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor.
Qing Y; Shuo W; Zhihua W; Huifen Z; Ping L; Lijiang L; Xiaorong Z; Liming C; Daiwen X; Yu H; Wei X; Min F; Zuohua F; Guanxin S
Cancer Immunol Immunother; 2006 Sep; 55(9):1111-21. PubMed ID: 16341531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
